Clinical trial NCT03977727
Conditions: Type 1 Diabetes Mellitus
Sponsor: Texas Diabetes & Endocrinology, P.A.
Start date: 2019-06-11; Completion date: 2020-04-20
Enrollment: 40 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with T1DM.

Detailed description:
This study is being performed to compare Fiasp® in terms of glycemic control with a focus on post-prandial 1-hour plasma glucose level and system-based outcomes to NovoLog® insulin when used in the Medtronic mini Med 670G HCL system (operating in auto-mode) in patients with type 1 diabetes. The investigator's hypothesis is that post prandial glucoses will be lower and time in range will be greater during the Fiasp® treatment period.

Subjects will have a 2 week screening period, 14 week treatment period and 30 Day follow up period. After at least 7 weeks on treatment period one they will crossover to treatment period two on the opposite treatment for 7 additional weeks.

Arms: arm 1: 7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion arm 2: 7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
Interventions: intervention 1: Fiasp® intervention 2: Novolog® intervention 3: 670G hybrid closed loop continuous subcutaneous insulin infusion system
Intervention descriptions: intervention 1: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system intervention 2: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system intervention 3: CSII

Protocol documents:
Prot_SAP_000.pdf: 
Trial ID: U1111-1213-9104                                                                                                                                       Version: 6.0 
Texas Diabetes & Endocrinology                                                                                                                Date:  16 APR 2019 
1 of  40 
 
 
 
 
 
 
An Exploratory, Single-center, Randomized, Open Label, Active-
control, Cross-over Trial Comparing the  Efficacy and Safety of 
Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin 
Aspart (Fiasp®) compared to NovoLog® used in the Medtronic 670G 
closed loop system in  Adults with Type 1 Diabetes 
 
 
 
Investigator – Sponsored Study Protocol 
UTN: U1111-1213-9104 
Trial Phase: IIIb 
 
 
 
 
 
Protocol originator 
Thomas Blevins, MD 
 Kerem Ozer, MD 
Texas Diabetes & Endocrinology 
6500 N Mopac Expwy Bldg 3, Suite 200 
Austin, TX 78731  USA 
P: 512.334.3505   F: 512.458.8593   
 
 


Trial ID: U1111-1213-9104                                                                                                                                       Version: 6.0 
Texas Diabetes & Endocrinology                                                                                                                Date:  16 APR 2019 
2 of  40 
 
 
Table of Contents 
                                                                                                                                                               Page 
Table of Contents………………………………………………………………………...…,………………2                       
1     Background and Significance………………………………………………………,…,………….…...3 
2     Flow Chart………………………………………………………………………………,……….….…5 
3     Rationale …………..……………………………………………………………………,……….….…7 
4     Research Design …………….…………………………………………………………,……….……..8 
5     Study Population…. .…………………………………………………………………,……….…...…11 
6     Methods and Assessments……………………………………………………………………….…….14 
7     Trial supplies……………………………………………………………………………….…….……27 
8     Randomization Procedure……………………………..…………………………………………..…..29 
9    Adverse events, Hypoglycemia, Hyperglycemia, Infusion Site reactions, and Pregnancies…….....….29 
10   Quality Control procedures……………………………………………………….……………….…..34 
11   Data Handling and Record Keeping ..………………………………………….………………….…..34 
12   Statistical considerations………………………………………………………..……………………..35 
13   Ethics……………………………………………………………………………….………………….37 
14  Protocol compliance……………………..………………………………………….…………….……38 
15  Audits and Inspections…………….………………………………………………….…………….….38 
16  Investigator Responsibilities….……………………………………………………………….…….…38 
17   Internal Review boards and regulatory authorities………………………….……………….………..39 
18  Publication Plan   …………………………………………………………………………….………..39 
29  References………………………………………………………………………………….…………..40 
 
 
 
   
 
 


Trial ID: U1111-1213-9104                                                                                                                                       Version: 6.0 
Texas Diabetes & Endocrinology                                                                                                                Date:  16 APR 2019 
3 of  40 
 
1 
Background and Significance 
 
Hybrid closed-loop (HCL) systems have been shown to improve glycemic control and reduce 
hypoglycemia by adjusting basal rates with the input of glucose data from continuous glucose monitoring 
to proprietary algorithms.(1) 
 
The Minimed 670G HCL (670G HCL) system has been shown to be associated with less glycemic 
variability, more time in target glucose range, low rates of hypoglycemia, and reductions in A1c. (2,3) 
 
The 670G HCL system has been studied using the rapid acting insulin analogues insulin lispro and insulin 
aspart (NovoLog®) The Minimed 670G System User Guide states that “Only use rapid acting U100 insulin 
(Humalog® (insulin lispro) and NovoLog® (IAsp) that has been prescribed by your healthcare professional 
for use with an infusion pump.” (4) 
 
The HCL system adjusts and controls basal insulin delivery. Mealtime bolus insulin is the responsibility of 
the user who must enter the amount of carbohydrates into a program in the insulin pump that calculates the 
amount of insulin to be delivered.  The timing of the pre-meal bolus is determined by the user as well. (4) 
 
One of the challenges of optimizing postprandial glucose control in an HCL system is slower than 
physiologic absorption of analog mealtime insulin (insulin lispro, insulin aspart, insulin glulisine).  
Patients with type 1 diabetes often comment that the bolus insulin doesn’t take effect fast enough to 
control mealtime carbohydrate or to lower the glucose when elevated (personal communication with 
numerous patients with Type 1 Diabetes using the insulin pump ). Faster acting insulin aspart (Fiasp®) 
with more rapid onset of action and peak than NovoLog® might help address this challenge. (5) 
 
 
Fiasp® is a new formulation which contains two additional excipients niacinamide and L-arginine.  
Niacinamide is responsible for faster initial absorption of insulin aspart after subcutaneous administration 
and L-arginine serves as a stabilizing agent. These additions result in earlier absorption of NovoLog® 
following subcutaneous injection. Fiasp® given by SC injection has been shown to have greater early 
glucose-lowering effect compared to NovoLog®.(6) 
 
The A1c lowering effect of mealtime Fiasp® has been shown to be non-inferior to NovoLog®  in subjects 
with Type 1 diabetes on MDI regimens.   In an active controlled randomized parallel-group trial, the 
Fiasp® arm had a statistically greater reduction in A1c compared to mealtime NovoLog®, and mealtime 
Fiasp® was shown to lead to superior postprandial glucose control relative to NovoLog®.  
 
In this trial, Fiasp® had a safety profile that was similar to NovoLog®  and the most common adverse 
event was hypoglycemia,-rate similar to NovoLog®  (7)   
 
Fiasp® has been studied in a non HCL insulin pump. A randomized, double blinded study comparing 
Fiasp® to NovoLog®  in patients using the MiniMed Paradigm Veo™754 insulin pump showed the 
following:  
 
 
 
 
 
 


Trial ID: U1111-1213-9104                                                                                                                                       Version: 6.0 
Texas Diabetes & Endocrinology                                                                                                                Date:  16 APR 2019 
4 of  40 
 
1. Fiasp® had an early glucose-lowering effect (area under the curve for glucose infusion rate [GIR]0-
30min) that was 2-fold higher than NovoLog® 
2. Fiasp® had an onset of glucose-lowering effect (time to early 50% of maximum GIR) that was 11.1 
minutes earlier (41.1 vs 52.3 minutes) 
3. Offset of glucose-lowering effect occurred 24.0 minutes earlier (214.7 vs 238.7) 
4.  Fiasp® and NovoLog® were both well tolerated. (5) 
 
 
In another double blinded crossover study comparing Fiasp® to NovoLog® in the MiniMed Paradigm_ 
pump (515/715, 522/722 or 523/723, Fiasp® led to significantly greater PPG lowering after a standardized 
meal test when compared to NovoLog®. In this trial, the one hour post meal test, PG levels were -29.47 
mg/dL lower with Fiasp® versus NovoLog®.  Continuous glucose monitoring (CGM) interstitial glucoses 
supported these findings with the largest differences being observed after breakfast: 163.57 vs. 172.19 
mg/dL. CGM date showed that the duration of low SMBG levels <70mg/dL per 24 h) was shorter for 
Fiasp® versus NovoLog®. (8) 
 
In a study investigating the compatibility of Fiasp® with the insulin pump, it was shown that over 6 weeks 
of treatment, no microscopically confirmed infusion-set occlusions were observed for Fiasp® or 
NovoLog®, indicating similar compatibility with insulin pump use. (9) 
 
It is possible that Fiasp® with its earlier onset and earlier offset of insulin effect  will lead to improved 
postprandial readings in patients on the Medtronic 670G HCL system.  This might lead to increased 
glucose time in range 
 
 
 
 
 
 
 


Trial ID: U1111-1213-9104                                                                                                                                       Version: 6.0 
Texas Diabetes & Endocrinology                                                                                                                Date:  16 APR 2019 
5 of  40 
 
2 
Flow chart 
 
Screening 
Randomization 
 
            Treatment Period 1 ( 7 weeks) 
 
Treatment Period 2 ( 7 weeks) 
 
End of treatment 
Follow-up  
Visit (V) 
Phone contact (P) 
V 
1 
V 
2 
P 
3 
P 
4 
V 
5 
P 
6 
V 
7 
 
V 
8 
P 
9 
P 
10 
V 
11 
P 
12 
V 
13 
V 
14 
P 
             15 
Time of visit  
-2 
0 
1 day 
after 
V2 
7 days 
after 
V2 
2 weeks 
after V2  
4 weeks 
after V2 
6 weeks 
after V2 
7 weeks 
after V2 
1 day 
after 
V8 
7 days 
after V8 
2 weeks 
after V8 
4 weeks 
after V8 
6 weeks 
after V8 
7 weeks 
after V8 
30 days after 
V14 
Visit window (days)1 
 
+3 
 
 
±1 
±1 
+3 
±3 
 
±1 
±1 
+3 
±3 
+7  
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomization criteria 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria for discontinuation 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Daily 4-point profile (SMPG) 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hypoglycemic episodes  
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Unexplained Hyperglycemic episodes 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Meal Test2  
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
Infusion site reactions 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Occlusion events 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body weight 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
BMI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vital signs 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 HbA1c 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 


Trial ID: U1111-1213-9104                                                                                                                                       Version: 6.0 
Texas Diabetes & Endocrinology                                                                                                                Date:  16 APR 2019 
6 of  40 
 
Visit (V) 
Phone contact (P) 
V 
1 
V 
2 
P 
3 
P 
4 
V 
5 
P 
6 
V 
7 
 
V 
8 
P 
9 
P 
10 
V 
11 
P 
12 
V 
13 
V 
14 
P 
             15 
Time of visit  
-2 
0 
1 day 
after 
V2 
1 week 
after 
V2 
2 weeks 
after V2  
4 weeks 
after V2 
6 weeks 
after V2 
7 weeks 
after V2 
1 day 
after 
V8 
1 week 
after V8 
2 weeks 
after V8 
4 weeks 
after V8 
6 weeks 
after V8 
7 weeks 
after V8 
30 days after 
V14 
Visit window (days)1 
 
+3 
 
 
±1 
±1 
+3 
±3 
 
±1 
±1 
+3 
±3 
+7  
Chemistry, Hematology 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
1,5-anhydroglucitol 
 
X 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
Fructosamine 
 
X 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
Urine Pregnancy testing3 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Infusion site exam 
 
X 
 
 
X 
 
X 
X 
 
 
X 
 
X 
X 
 
Pairing of Subjects Pump and Subject Number in 
Carelink 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instruct in use of BG meter  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hand out and instruct in use of diary 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
 
 
Training in diabetes and carbohydrate counting4 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Training in pump use4 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Remind Subjects to bring BG meter to site visit 
X 
 
 
X 
 
X 
X 
 
 
X 
 
X 
X 
 
 
Upload pump/ BG meter data into Carelink 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dose adjustments/Pump Setting Review 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Instruct in use of trial product5 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Drug Accountability5 
 
X 
 
 
 
 
X 
X 
 
 
 
 
X 
X 
 
Drug Dispensing5 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
End of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Attend visit fasting6 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
Remind subject to change sensor prior to meal test 
visit
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
1 Visit windows are relative to randomization (Visit 2) and Treatment Period 2 Start (Visit 8) and End of Treatment 
2 Meal tests should not be performed on days of  the CGM sensor insertion or on Day 7 of the current sensor session. Meal test will consist of  blood draws at the following time points: 
-2 min, 0 min, 30 min, 60 min, 120 min, and 180 min 
3 Urine pregnancy testing to be performed on women of child bearing potential only 
4 To be performed by qualified site staff  
5At Visit 2 (Randomization) study medication will be dispensed.. At visit 8 (Treatment period 2) study medication will be dispensed.  
6 Fasting is considered 8 hours with no food or drink, other than water  


 
7 of  40 
 
 
3 
Rationale  
 
The Medtronic 670G HCL system offers closer to physiologic algorithm based insulin delivery 
with variable basal insulin administration which interacts with CGM derived, glucose levels.   
Slower than physiologic insulin effect at mealtime limits the ability to control the postprandial 
excursions in patients on insulin pumps including HCL systems.  It is expected that Fiasp® in the 
670G HCL system would lead to better postprandial control with more rapid insulin onset of 
effect. More rapid offset of insulin action might lead to less post meal hypoglycemia.  Using 
Fiasp® in the 670G HCL might lead to improved % of time in range with its more rapid effect 
with pulses of insulin in the basal algorithm and lower post prandial glucose.   
Fiasp® has not been studied in the 670G HCL system to date and its potential for optimizing 
glycemic control in the 670G HCL system needs to be evaluated. 
The purpose of this study is to compare the efficacy and safety of Fiasp® versus NovoLog® in the 
Minimed 670G HCL system in T1DM subjects. 
Both CGM and a standardized meal test will be used to evaluate the effect of Fiasp® vs. 
NovoLog® on postprandial glucose excursions in subjects on “Auto Mode” (active use of the 
HCL feature of the 670G). Time in range will be based on data downloaded from Medtronic 
Carelink data management software. The meal test will compare the physiological effect on post-
prandial glucose of  Fiasp® vs. NovoLog® at the end of each treatment period.  The use of a 
weight-based insulin dose calculation for the meal test aims to minimize inter-subject variability 
in insulin sensitivity. This will allow us to study insulin effect in a more direct manner, and gain 
insight into postprandial physiology. 
7 week treatment periods during each crossover period will allow time for adjustment of the 
settings (I:CR and active insulin time) at appropriate intervals such as might be done in a clinical 
practice and then allow for 2-3 weeks of stable dosing to determine time in range during stable 
dosing (recognizing that the only settings that can be adjusted are I:CR and active insulin time). 
The 3 weeks after the dose adjustment period of stable dosing will compare the “time in range” 
in the Fiasp® vs. NovoLog® group in the 670G Hybrid Closed Loop System.  The measurement 
of time in range during the post dose adjustment period makes this a more clinical, real world 
study as it compares efficacy over a period of weeks. 
 
 
 


 
8 of  40 
 
 
 
 
4 
Research Design  
Our hypothesis is that post prandial glucoses will be lower and time in range will be greater 
during the Fiasp® treatment period. 
Objectives  
Primary objective 
To compare Fiasp® in terms of glycemic control with a focus on post-prandial 1-hour plasma 
glucose level and  system-based outcomes to NovoLog® insulin when used in the Medtronic 
mini Med 670G HCL system (operating in auto-mode) in patients with type 1 diabetes.  
Secondary objectives 
- Assessment of post-prandial glucose regulation (Continuous glucose monitor data, and 1,5 
anhydroglucitol levels) 
- Evaluation of cumulative glycemic control (HbA1c) 
- Measurement of HCL parameters  
- Reporting of Fructosamine levels 
Endpoints 
Primary Endpoint 
- Post-prandial 1-hour plasma glucose levels at 6 weeks into start of therapy in each arm  
Secondary Endpoints  
- Post- prandial 2- hour plasma glucose levels at 6 weeks into start of therapy in each arm 
- HbA1c and 1, 5 AG levels prior to cross-over, and at end of study 
- 
Glycemic excursion parameters: Time spent within glycemic ranges as below will be 
reported and analyzed. Time spent in specific ranges will be expressed as a percentage of 
total time on treatment. 
o Time spent (%) within 70-180 mg/dl 
o Time spent (%) < 70 mg/dl  
o Time spent (%) >200 mg/dl 
o Hypoglycemia (differentiated as level 1 or level 2) (Reference 11) 
o Severe hypoglycemia 
 
- 
Insulin related parameters 


 
9 of  40 
 
o Total daily dose 
o change in %bolus and %basal from baseline 
o Auto basal / basal amount (per day) 
o Change in insulin : carbohydrate ratio from baseline  
o Active insulin time 
- 
Pump related parameters 
o Time spent (%) in auto mode 
o Time spent (%) in manual mode 
o Auto mode exits (with reasons for exit)  
o Infusion site reactions reported by patient 
o Occlusion events reported by patient 
 
This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-
over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic 
MiniMed 670G system in subjects with T1DM.  
Study timeline: 
FPV expected to be April 2019 with LPV in January 2020.The total duration of the trial 
participation for subjects is approximately 20 weeks as shown below:  
Visit 1: Screening 
Visit 2: Randomization /Treatment Period 1 Start / Day 0 
Visit 3: Phone visit / 1 day after randomization 
Visit 4: Phone visit / 1 week after randomization 
Visit 5: Office visit / Week 2 
Visit 6: Phone visit / Week 4 
Visit 7: Office visit / Week 6 / Meal test 
Visit 8: Office visit / Week 7/ Treatment Period 2 Start  
Visit 9: Phone follow-up / 1 day  after Visit 8 
Visit 10: Phone follow-up / 1 week after Visit 8 
Visit 11: Office visit / Week 9 
Visit 12: Phone follow-up / Week 11 
Visit 13: Office visit / Week 13 / Meal test 
Visit 14: Office visit Week 14 
Visit 15: 30-day follow-up after EOT (phone)  


 
10 of  40 
 
The screening visit assesses subjects’ eligibility. Eligible subjects will enter a two-week 
screening period. The screening period will provide subjects with an opportunity to become more 
familiar with the HCL, and will give the investigator opportunities to focus on pump use review, 
and review and training in study procedures as needed.  
After the screening period, the subjects will be randomized (visit 2) to NovoLog® or Fiasp®. 
After 7 weeks on the initially assigned regimen, a cross-over will occur at Visit 8.  
 
Rationale for study design  
The screening period has been included to optimize HCL use, and assure adequate training of 
subjects in study procedures.  
The 7-week randomized treatment period is needed to collect valid and adequate data to analyze 
safety and efficacy. A cross-over design will provide adequate control data.  
The 6-week post-prandial readings and 1,5-AG levels will provide data on post-prandial 
glycemic control, and time-in-range and HbA1c measurements will provide data on cumulative 
glycemic control.  
Fructosamine levels indicate the average level of blood glucose control over the past 2-3 weeks.  
These levels may be a more accurate measure of average blood glucose control after a 6 weeks 
treatment period than A1c which measures average glucose control over 2-3 months. 
Safety will be assessed via hypoglycemia records, patient logs, and HCL parameters.  
Treatment principles 
During the screening period, the main focus will be ensuring all subjects are familiar with the 
HCL system, trouble-shooting potential problems, and reviewing study procedures. If the 
Investigator feels the subject should extend the screening period to further ensure familiarity 
with the HCL system, this will be allowed once.   
In the treatment period, the investigators will strive to achieve glycemic targets of fasting and 
pre-prandial levels of 70-110 mg/dL in a treat-to-target fashion. All subjects must perform 
glucose calibration measurements as dictated by the 670G system CGM requirements.  
At end of  the treatment period, subjects will be switched to suitable approved regimen at the 
discretion of the investigator.  
 
 


 
11 of  40 
 
5 
Study population 
 
5.1 
Number of Subjects 
 
Number of Subjects planned to be screened: 
45 
 
 
Number of Subjects planned to be randomized: 
40 
 
 
5.2 
Inclusion criteria 
 
For an eligible Subject, all inclusion criteria must be answered "Yes". 
 
1.   Informed consent obtained before any trial-related activities. Trial-related activities 
are any procedures that are carried out as part of the trial, including activities to 
determine suitability for the trial 
 
2.   Male or female, age ≥18 years at the time of signing informed consent 
 
3.   Documented diagnoses of T1DM ≥1 year prior to the day of screening 
 
4.   Using the Medtronic pump Minimed 670G for CSII in a basal-bolus regimen with 
a rapid acting insulin analogue for at least 30 days prior to screening and willing to 
continue using their personal Medtronic Minimed 670G and CSII for insulin 
treatment throughout the trial.  
 
5.   Ability and willingness to use the same insulin infusion sets throughout the trial 
 
6.   Using the same insulin for at least 30 days prior to screening 
 
7.   HbA1c < 8.5% as assessed by local laboratory at screening 
 
8.   BMI ≤ 35.0 kg/m2 at screening 
 
9.   Ability and willingness to adhere to the protocol including performing 
SMPG profiles, attending visits, utilizing the auto mode feature of the pump 
for at least 80 % of the time during the study, and completing meal tests 
 
 
5.3 
Exclusion criteria 
 
For an eligible Subject, all exclusion criteria must be answered "No". 
 


 
12 of  40 
 
1.   Known or suspected hypersensitivity to trial products or related products 
 
 
2.  Female who is pregnant, breast-feeding or intends to become pregnant or is of 
child-bearing potential and not using adequate contraceptive methods (adequate 
contraceptive measures as required by local regulation or practice) 
 
3.   Participation in another clinical trial within 28 days before the screening visit. 
Note: clinical trials do not include non-interventional studies 
 
4.   Anticipated significant change in lifestyle (e.g. eating, exercise or sleeping pattern) 
throughout the trial 
 
5.   Any of the following: myocardial infarction, stroke, hospitalization for unstable 
angina or transient ischemic attack within the past 180 days prior to the day of 
screening 
 
6.   Subjects classified as being in New York Heart Association (NYHA) Class IV at 
      screening    
 
 
7.   Planned coronary, carotid or peripheral artery revascularization known on 
the day of screening. 
 
 
8.   Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic 
≥180 mmHg or diastolic ≥110 mmHg) at screening 
 
9. Impaired liver function, defined as ALT ≥ 2.5 times upper normal limit at screening 
 
10. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of  
< 45 ml/min/1.73 m2  
 
11. Anticipated initiation or change in concomitant medications (for more than 14 
consecutive days) known to affect weight or glucose metabolism in the opinion 
of the Investigator 
 
12. Proliferative retinopathy or maculopathy requiring acute treatment at the time of 
screening 
 
13. History of hospitalization for ketoacidosis ≤180 days prior to the day of screening 
 
14. Treatment with any medication for the indication of diabetes or obesity other 
than stated in the inclusion criteria within 30 days before screening 
 


 
13 of  40 
 
15. Presence of malignant neoplasms at the time of screening. Basal and 
squamous cell skin cancer and any carcinoma in-situ is allowed. 
 
       16. Reoccurring Severe hypoglycemia while on the Medtronic Minimed 670G in the 
investigators opinion   
17. Any condition which, in the opinion of the Investigator, might jeopardize 
Subject’s safety or compliance with the protocol 
 
5.4        Randomization criteria 
 
To be randomized, the below randomization criteria must be 
answered "Yes". 
 
1. Subjects ability and willingness to adhere to the protocol and satisfactory handling 
of the pump, including regular changes of the infusion sets, utilization of the auto 
mode feature of the pump for at least  80 % of the time, and adequate bolus dosing 
based on the Investigator’s judgment. 
 
5.5        Criteria for premature withdrawal from trial 
 
Efforts should be made to ensure Subjects attend and complete all scheduled visits and 
procedures.  
 
5.5.1 
Withdrawal from trial 
 
The Subject may withdraw at will at any time. The Subject’s request to discontinue 
from the trial must always be respected. The investigator may withdraw the subject at 
any time due to safety or non- compliance.  
 
If a Subject decides to withdraw consent or the Investigator withdraws the Subject, the 
Subject should be asked to undergo procedures described in Section 2. 
 
A Subject will be considered “lost to follow up” if the Subject repeatedly fails to attend the 
scheduled visits and the site is unable to establish contact to the Subject. The following 
actions must be taken by the site in relation to a Subject who fails to attend the site for a 
scheduled visit: 
 
• The site should attempt to contact the Subject and to reschedule the missed visit 
as soon as possible 
• The site should re-train the Subject in the importance of maintaining the scheduled visits 


 
14 of  40 
 
• In cases where a Subject is deemed lost to follow up the Investigator must make 
every effort to regain contact to the Subject  
 
5.6 
Subject replacement 
 
Subjects who are withdrawn after randomization (Visit 2) will not be replaced. 
 
5.7 
Rationale for trial population 
 
40 patients, accounting for 10% dropout rate, to achieve 80% power to detect 32 mg/dl treatment 
difference  
 
6 
Methods and Assessments 
 
6.1 
Visit procedures 
 
The following sections describe the assessments and procedures. Timing of the different 
assessments and procedures including type of visit and the visit windows are also 
described in the flowchart in section 2. 
 
 
 
 
 
6.1.1 
Informed Consent 
 
Before any screening activities take place, the Subjects must be provided with written 
and oral information about the trial, the procedures involved and their responsibilities 
and rights while participating in the trial, in accordance with ICH-GCP and local 
requirements. The Subjects will also be informed about possible 
advantages/disadvantages when being treated with trial products. The Subjects will 
have the opportunity to ask questions and will have ample time to consider 
participation. 
 
Subjects who wish to participate in the trial will sign and date the Subject Informed 
Consent before any trial-related procedures commence. Trial-related activities are any 
procedures that would not have been performed during the normal management of the 
Subject. All Subjects must be provided with a copy of their own signed and dated 
Informed Consent. 
 
6.1.2 
Screening visit 
 


 
15 of  40 
 
At screening (Visit 1), each Subject’s will be assigned a unique 3-digit Subject number 
which will remain the same throughout the trial.  
 
Any abnormal and clinically significant findings at Visit 1 must be recorded on 
the medical history/concomitant illness form in the source documentation 
 
For screening (Visit 1) procedures, please see flowchart in section 2. 
 
6.1.2.2 
Re-screening 
 
Re-screening is allowed once if the subject has failed one of the inclusion or 
exclusion criteria related to laboratory parameters.  
 
6.1.3 
Randomization 
 
Randomization (Visit 2) should occur after the screening period has been completed. 
 
 
Randomization can take place as soon as the Subject has been found eligible and should 
take place no later than 30 days after screening (Visit 1). The results of all the screening 
assessments must be available (including central laboratory results) and must have been 
reviewed by the Investigator before the Subject can randomize.    
 
If the Subject meets the randomization criterion at Visit 2, the Subject will be randomized into 
one of the two treatment arms for the first cross-over period.  Subjects will change their pumps 
to manual mode for 1 week post- randomization. After the 7 day manual mode wear, the subject 
will turn the pumps on auto mode for the remainder of the treatment period. 
 
For randomization (Visit 2) procedures, please see flowchart in section 2. 
 
 
 
6.1.4 
Site visits 
 
If a visit to the site is not performed as scheduled for any reason, then the Investigator 
should arrange for the visit to be performed as soon as possible and within the visit 
windows specified in section 2. 
 
Scheduled dispensing of trial product should be performed at the visits indicated in the 
flowchart in section 2. Drug accountability should be performed at each dispensing visit 
from start of randomization (Visit 2) until end of treatment (Visit 14). 
 
For assessments performed at the site visits, please see flowchart in section 2. 
 


 
16 of  40 
 
6.1.5 
Phone contacts 
 
Before any phone contact, both the Investigator and Subject should agree on the date, 
timing and direction of the call. The Investigator remains responsible for ensuring that the 
phone contacts occur even if it is agreed that the Subject should call the site. 
 
If a planned phone contact is, for some reason, not performed at the agreed time point, 
the Investigator must arrange for the phone contact to be performed as soon as possible 
and within the scheduled visit windows specified in section 2. A phone contact visit may 
be converted to a site visit if needed. 
 
The withdrawal criteria should be reviewed during the phone contact to ensure the 
Subject is eligible to continue in the trial. 
 
For assessments performed at the phone contacts please refer to the flowchart in section 2. 
 
6.1.6 
Fasting visits 
 
Fasting is defined as no intake of drink or food for at least 8 hours prior to blood 
sampling (only water is allowed). The Subjects must attend the visits specified in 
section 2 in a fasting condition. Correction boluses are allowed until four hours before 
the measurement of the FPG.  
 
Bolus insulin dosing and medication which should be taken with or after a meal should be 
withheld until blood sampling has been performed. Any other concomitant medication 
can be taken as usual. 
 
If the Subject attends the fasting visits in a non-fasting condition, all blood samples and 
meal test must be rescheduled within the visit window.  
 
 
6.1.7 
Withdrawal procedures 
 
6.1.7.1        Withdrawal from trial 
 
If a Subject withdraws consent from the trial after randomization (Visit 2), the 
Investigator must ensure every possible effort is made to undertake procedures same as 
those for end of treatment (Visit 14) including the meal test, as soon as possible after 
decision of ending trial. The meal test should be performed with trial product according 
to randomization unless this is not feasible due to safety reasons as judged by the 
Investigator. 
The Subject should also complete the follow-up visit (Visit 15). Final drug accountability 
must be performed even if the Subject is not able to come to the trial site. 


 
17 of  40 
 
 
Although a Subject is not obliged to give his/her reason(s) for withdrawing from a trial, the 
Investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the 
 Subject's rights. Where the reasons are obtained, the primary reason for not completing the trial 
must be   specified within the source documentation. 
6.1.8 
Crossover (Visit 8) 
 
At Visit 8 cross over the subject’s will be dispensed study medication and switched to the 
comparative  trial product . The Subject’s will be instructed to change their pumps to manual 
mode for 1 week after the start of the crossover period.  After 7 days of manual mode then 
subject will turn on auto mode for the duration of the treatment period.  
 
6.1.9 
End of treatment (Visit 14) 
 
At end of treatment (Visit 14), the trial product should be discontinued and a stop date of trial 
product must be recorded in the source documentation. 
The Subject should be switched to a suitable marketed product at the discretion of the 
Investigator and this product should be recorded on the source documentation. For 
procedures to be performed at end of treatment (Visit 14), please see flowchart in section 
2. 
 
  6.1.10 
Follow-up 
 
The follow-up period is a 30-day follow-up (Visit 15) relative to the end of treatment 
visit (Visit 14). 
 
6.1.10.1 
Follow-up  (Visit 15) 
 
During the 30-day follow-up period (Visit 15) the following information will be 
collected: 
 
• AEs 
• Concomitant medication 
• Concomitant diabetes medication 
• Hypoglycemic events   
• Unexplained hyperglycemic events  
 
6.2 
Subject related information 
 
6.2.1 
Demography  
 
The following demographic data will be obtained by the Investigator: 
 
• Date of birth  
• Age at screening 
• Ethnicity  


 
18 of  40 
 
• Race  
• Sex 
 
6.2.2 
Diagnosis of Type 1 Diabetes Mellitus  
 
At screening (Visit 1) the date of diagnosis of T1DM, as part of the medical history intake, 
will be obtained.  
 
6.2.3 
Concomitant illness and medical history 
 
A concomitant illness is any illness, except T1DM, that is present at the start of the 
trial (i.e. at screening (Visit 1) or found as a result of the screening procedures. 
 
Any change to a concomitant illness should be recorded in the source documentation. A 
clinically significant worsening of a concomitant illness must be reported as an AE as 
described in section 12. 
 
Medical history is a medical event that the Subject has experienced in the past. 
Only relevant medical history, as judged by the Investigator, should be reported. 
 
The information collected for concomitant illness and medical history should include 
diagnosis, date of onset, date of resolution, or continuation, as applicable. 
 
                6.2.4               Childbearing potential 
 
It must be recorded in the source documentation whether female Subjects are of childbearing 
potential. 
 
Female of non-childbearing potential is defined as, but not limited to: 
• A female who has undergone a hysterectomy, bilateral oophorectomy, uterine 
ablation or bilateral tubal ligation 
• Postmenopausal defined as no menses for 12 months without an alternative medical 
cause 
• Other medical reasons preventing childbearing potential 
 
Pregnancy testing must be performed on females with childbearing potential, as described in 
Section 2. 
 
The Subjects must be instructed to use approved contraceptive methods, throughout the 
trial and until 1 week after end of treatment. 
 
6.3       Clinical assessments 
 
   6.3.1 
  Concomitant medication 
 


 
19 of  40 
 
A concomitant medication is any medication, other than trial products and diabetes 
medication which is taken during the trial, including in the screening, treatment,  and 
follow-up periods. 
 
Details of any concomitant medication must be recorded in the source documentation at 
screening (Visit 1). Any changes in concomitant medication must be recorded at each 
visit or phone contact as they occur. The information collected for each concomitant 
medication includes (at a minimum) trade name or generic name, indication, start date, 
and stop date (or continuation). 
 
If a change is due to an AE, then this must be recorded and reported according to 
section 09.  
 
 
      6.3.2 
  Use of Pumps and BG 
meters 
 
During the trial, from start of the randomization period (Visit 2) until end of treatment 
(Visit 14), each time the Subjects attends a site visit the following data will be uploaded 
to Medtronic CareLink (a web based database): 
 
• All BG meter data transferred to the pump 
• All pump data 
 
Data uploaded from the insulin pump include SMPG values, insulin doses, dose 
calculation related data (e.g. carbohydrates, carbohydrate ratio and insulin sensitivity), 
primes and rewinds, alarms and other pump settings. Once data has been uploaded to 
Medtronic CareLink the Investigator will use the reports generated to: 
 
• Check Subject treatment and compliance 
• Make adjustments to the Subject’s treatment 
• Reconcile data entered in the Subjects diary 
 
 
6.3.2.1 
Insulin dose 
It is recommended that the bolus dose should be established by Subjects using the Bolus 
Wizard® according to their usual practice based on instructions from the Investigator. 
 
6.3.2.2 
Self-measured plasma glucose 
 
At Screening (Visit 1) the Subject will be required to use their personal BG Contour® 
meter and supplies during the study. If the subject is not able to use their own supplies, 
they will be provided with a BG Contour® meter, including lancets and test strips for BG 
meters. The Subject will be instructed verbally on how to use the device according to the 


 
20 of  40 
 
manufacturer’s instructions, as needed. The Subject will also be provided with written 
instructions as needed. Sites will, as necessary, go through the instructions of use with the 
Subject during visits to the site. 
 
Throughout the trial, only the BG Contour® meter specifically designed to pair with 
the Medronic 670G pump must be used to measure the plasma glucose values. 
 
The BG Contour® meter and the pump should be confirmed to be linked by the site 
personnel at Screening (Visit 1) by review and/or entering the BG Contour® meters 
Identifications number into the pump to ensure SMPGs are automatically transferred 
to the pump. The BG Contour® meter must be set to transfer all SMPG values 
automatically. 
 
The Subjects must be instructed to bring their BG Contour®  meter to the site at every 
visit. The site personnel must upload the data from the BG Contour® meter into Medtronic 
CareLink at every site visit. 
 
The Investigator will be able to review the SMPG profiles in Medtronic CareLink reports 
and use them to evaluate the Subject’s glycemic control and make adjustments to the 
pump settings in order to optimize insulin titration. 
 
 
For the following episodes additional information needs to be recorded in the diary: 
 
• If a SMPG value is ≤ 70 mg/dL, the Subject should record the hypoglycemic 
episode. 
• If a SMPG value is > 70 mg/dL, but the Subject feels typical symptoms of 
hypoglycemia and interprets those as indicative of hypoglycemia, the subject 
should record symptoms and glucose level. 
 
• If an SMPG value is ≥ 300 mg/dL, the Subject should record only the 
unexplained hyperglycemic episodes. 
The Investigator should check whether the Subject has recorded the episodes in the 
hypoglycemia and unexplained hyperglycemia section of the diary, by comparing the 
diary with the Medtronic CareLink report. If not, the missing information needs to be 
filled in by the Subject during the visit. 
 
4-point self-measured plasma glucose profile  
 
Subjects will be instructed to perform 4-point profiles every day during the conduct of 
the trial (from Visit 1 to Visit) mainly for titration purposes. The SMPGs should be 
measured at the following time points: 
 
• Before breakfast  


 
21 of  40 
 
• Before lunch 
• Before main evening meal 
• At bedtime 
 
SMPG measurements before breakfast should be performed in a fasting condition. 
SMPG measurements before lunch, main evening meal, and at bedtime should be 
performed before any bolus insulin infusion.  
 
6.3.2.3 
Change of infusion set and reservoir 
Infusion sets will not be provided by the study. The subjects should be able to continue to 
afford and use their own personal infusion sets throughout the entire study period.  The 
type of infusion set should be recorded in the source documentation at screening and the 
subjects should remain on the same type of sets throughout the duration of the entire 
study period. 
 
The Subjects should be instructed to routinely change infusion set in intervals not 
exceeding 3 days (2 days for SureT® (Easy-set®)). Infusion set and reservoir should be 
changed at the same time. The trial products should preferably be administered in the 
abdominal wall. The Investigator should ensure that the Subject is instructed in the 
following: 
• The infusion region chosen should remain unchanged throughout the trial 
• The infusion site should be rotated within the same region 
• The infusion set should preferably be inserted in the same way 
 
The Subject should change infusion set and reservoir at the site under supervision by 
the Investigator at randomization (Visit 2) and at end of treatment (Visit 14) due to the 
change from pre-trial insulin to trial product. The Investigator should evaluate the skin 
for any local skin irritation or skin infection at every office visit. Any abnormal 
clinically significant findings should be recorded as an infusion site reaction, as detailed 
in Section 7. 
 
 6.3.2.4 
Training in pump use 
 
At start of the screening period (Visit 1), the Investigator should ensure that the Subject 
knows how to use the insulin pump and perform appropriate training. The Investigator 
will repeat the training at the randomization visit. The Investigator should ensure that the 
Subjects know about the following: 
• How to set the time and date on their pump 
• Importance of maintaining the correct time and date (e.g. when traveling 
or entering time changes due to daylight savings) 
• How to ensure the SMPG values are recorded in the pump 
• Pump settings including settings for basal rates and bolus doses 


 
22 of  40 
 
• Dose adjustment of insulin and use of Bolus Wizard® 
• When to perform a routine and non-routine change of infusion set and reservoir 
• How to report infusion set change information 
• Filling reservoir from vials including priming of infusion set and checking for 
air in the infusion set before insertion of reservoir 
• Carbohydrate counting 
• Troubleshooting in case of hypoglycemia and hyperglycemia 
• When and how to measure ketones  
• Troubleshooting in case of pump failure or any technical problems with the pump 
• Proper sensor change techniques and timing 
• Auto mode features and use  
• Use of acetaminophen in conjunction with sensor use  
• Standard 3 hour active insulin time will be used. This may be changed at the 
investigators discretion 
• Standard bolus speeds will used 
• Standard target of 120 mg/dL will be used during auto mode 
 
 
The Subjects should be instructed to call the site in case of any episodes of pump 
failures (e.g. technical problems or software problems) as well as to contact the pump 
manufacturer’s technical support. The Investigators should record this pump failure 
incident in the Subject medical record. 
 
 
6.3.2.5 
Training in diabetes and carbohydrate counting 
 
All Subjects should have reinforced diabetes training including carbohydrate counting 
e.g. sessions with a diabetes educator, dietician or qualified site staff (i.e. diabetes 
specialized nurse) according to local practice.  
 
It is the Investigators responsibility to ensure that the Subject is adequately trained 
during the trial and has a satisfactory knowledge in: 
• Recognition of carbohydrates in commonly eaten foods 
• Ability to count the carbohydrate content in typical portions of simple foods 
• Ability to interpret a nutrition label for carbohydrate content 
• Glycemic targets  
• Preventing and treating hypoglycemia using carbohydrate foods 
• Ability to sum up the carbohydrate content of a meal 
 
6.3.3 
Body measurements 
 
 


 
23 of  40 
 
Height (without shoes) will be measured at screening (Visit 1) only and recorded 
rounded to the nearest centimeter (cm). 
 
Body weight should be measured in kilograms (kg) without overcoat and shoes, and 
wearing only light clothing. Body weight will be recorded to one decimal place. 
 
The body weight should be assessed on the same calibrated weighing scale equipment 
throughout the trial, if possible. 
 
BMI will be calculated by kg/m2 . 
 
     6.3.4 
      Meal test 
 
The Subject will undergo a standardized liquid meal test at certain visits (see section 2).  
During that time 5 blood samples will be drawn, as specified in section 2. The samples will be 
analyzed by the local laboratory. The Subject must attend the meal test visits in a fasting 
condition. Bolus infusion and other medication which should be taken before, in a relation to or 
after a meal should be withheld until the meal test has been performed. 
The Subject should before the meal test be instructed to: 
• Follow normal routine regarding eating and exercise habits on the day prior to the meal 
test 
• Refrain from intake of alcohol on the day prior to the meal test 
• Change infusion set and reservoir prior to the visit so that the meal test is not completed 
on the day of a sensor change or on day 7 of the current sensor wear 
• 
Take a correction bolus according to guidance from Bolus Wizard® if the PG value 
above the target level. There should be a minimum of four hours between any correction 
bolus dose and the start of the meal test. 
Any hypoglycemic episodes from midnight before the meal test should be treated and the 
hypoglycemic episode should be recorded in the diary.  At the investigator’s discretion, the meal 
test should be re-scheduled within the visit window. 
The Subject should have SMPG values within a range of  71-180 mg/dL  before beginning the 
meal test and bolus insulin dosing. The SMPG values should be verified and recorded at the site 
before starting the meal test. If the Subject is not fasting or the SMPG value is outside the range, 
at the Investigators discretion, the meal test should be rescheduled within the visit window.. The 
Subject’s body weight must be measured and a blood sample must be drawn two minutes before 
intake of the standardized liquid meal. The bolus insulin dose should be calculated by the 
Investigator based on the dose level of 0.1 unit/Kg body weight. The calculated dose should be 


 
24 of  40 
 
rounded to the nearest whole unit. The 0.1 unit/kg dose is chosen as an approximation of a 
clinically relevant bolus dose needed for the given size of a standardized meal for T1DM. The 
use of a weight-based insulin dose calculation for the meal test was specifically chosen to be 
used in the study in order to minimize inter-subject variability.  Only a normal bolus type is 
allowed. The start of bolus infusion will be defined as time point 0. The Subject will have a 
carbohydrate-rich standardized meal served immediately after bolus infusion and must consume 
this as quickly as possible (within 15 minutes). The Investigator should confirm that the Subject 
consumed the required volume of the standardized liquid meal and actual clock time of start of 
infusion and meal consumption should be noted. The standardized meal will be provided by the 
site. The volume of the standardized meal to be consumed should be measured out by the 
Investigator to be the equivalent to 78 grams of carbohydrate. 
Time points of blood glucose obtained during the meal test will be as follows: -2 min, 0 min, 30 
min, 60 min, 120 min and 180 min.  
No smoking or intake of meals and liquids will be allowed during the meal test, except for water. 
 
If SMPG values ≤  70 mg/dL are measured then the hypoglycemia should be treated 
according to site practice and the meal test should continue according to the Investigator’s 
discretion. The hypoglycemic episode must be reported.  
After the meal test, the Investigator should make sure that the Subject is safe to leave the site confirmed 
by an additional SMPG value. 
 
    6.3.5 
      Site insertion examination 
 
The site insertion examination will be performed as outlined in the flow chart 
(section 2). Site insertion examination will include a skin examination of the 
subjects preferred infusion set site insertion. 
 
Any abnormal and/or clinically significant findings must be recorded in the Subject’s 
medical record or reviewed for an adverse event. 
 
Any clinically significant worsening from screening, as well as any new abnormal and 
clinically significant findings, must be reported as an AE in accordance with section 9. 
 
 
            6.3.6       Vital signs 
 
Diastolic blood pressure, systolic blood pressure and pulse should be assessed while the 
Subject is in a sitting position after five minutes of rest. If the Subject is using 
antihypertensive medication to control the blood pressure, then the medication should be 
taken as usual prior to assessing vital signs. 
 


 
25 of  40 
 
Vital signs will be assessed according to the flow chart, please see section  2.  
 
Any abnormal and/or clinically significant findings at screening (Visit 1) must be recorded in 
the Subject’s medical record. 
 
Any clinically significant deterioration of a pre-existing condition, as well as any new 
clinically significant signs or symptoms, should be reported as an AE in accordance 
with section 09. 
 
 
6.4                Laboratory assessments 
 
Except for urine pregnancy testing, all laboratory analyses will be performed by a local 
laboratory contracted by the Investigator. The local laboratory will provide all laboratory 
supplies for the sampling and transportation of all blood and urine samples taken during 
the trial.  
 
Laboratory samples can be drawn on another day than on the day of the actual visit, as 
long as it is within the visit window, as stated in the flowchart in section 2. 
 
If laboratory samples need to be retaken due to missing result(s) (e.g. hemolyzed, sample 
leaked during transit, sample not being conclusive, lost in transit, etc.), the Subject should 
be called in for resampling.  
 
6.4.1 
1,5-anhydroglucitol 
 
  1,5 –anhydroglucitol is measured in order to evaluate post prandial glucose control. Please see 
section 2. 
 
 
 
6.4.2 
HbA1c 
 
Blood samples will be drawn as specified in the flow chart (section 2) to determine the 
HbA1c level in order to evaluate glycemic control. 
 
 
6.4.3 
Pregnancy testing 
 
For females of childbearing potential, a urine pregnancy test will be performed at the 
visits, as detailed in the flowchart in section 2. In addition, urine pregnancy tests will be 
performed locally during the trial if a menstrual period is missed or if deemed necessary 
by the Investigator or required by local law. A positive urine pregnancy test should be 
followed by a confirmatory serum-hCG (local laboratory). 
 


 
26 of  40 
 
6.4.4 
Fructosamine 
   
  Fructosamine levels indicate the average level of blood glucose control over the past 2-3 weeks  
  Please see section 2. 
  
 
6.5 
Other assessments and procedures 
 
6.5.1 
Diary 
 
Diaries will be used in this trial and handed out to the Subjects as specified in section 2. 
At End of treatment the Subjects have to return their last diaries. 
 
The Investigator must carefully instruct the Subject in how to fill out the diary. The 
Subject should bring the diary at each visit to the site and there the Investigator or 
delegated site personnel must review the diary together with the Subject to ensure 
consistency/compliance. If clarification of entries is needed or discrepancies in the diary 
are found, the Subject must be questioned and a conclusion made in the Subject's medical 
record.  
The following data will be captured by the Subject in the diary: 
 
• Hypoglycemic episodes 
• Unexplained hyperglycemic episodes (including any urine/blood ketone values 
measured, if available) 
 
 
 
6.5.1.1 Hypoglycemic episodes 
 
All plasma glucose values: 
• ≤ 70 mg/dL 
• > 70 mg/dL occurring in conjunction with hypoglycemic symptoms 
 
 
Plasma glucose should always be measured and recorded by the Subject in the 
diary, when a hypoglycemic episode is suspected.  Hypoglycemic episodes should 
be reported in the diary according to the instructions below throughout the trial 
from Visit 1 to End of treatment. 
 
 
In case of several low SMPG values within the 60 minutes interval, the first value taken 
is the one that will be reported as the SMPG value for the hypoglycemic episode. 
 
 
6.5.2 
Occlusion event reporting  
 
 


 
27 of  40 
 
Starting from randomization (Visit 2) until the end of treatment (Visit 14) the subjects will be 
questioned at each visit on the occurrence of infusion set occlusions.  Occlusion events, for this 
trial, are defined as a premature change of an infusion set prompted by suspicion of occlusion, 
leakage, or unexplained hyperglycemia.  Subjects will be asked to return any infusion sets to the 
site, that are thought to have been occluded, for the site to view.  
 
 
 
6.6 
Subject compliance 
 
Throughout the trial, the Investigator will remind the Subjects to follow the trial 
procedures and requirements to ensure Subject compliance. If a Subject is found to be 
non-compliant, the Investigator will remind the Subject of the importance of following the 
instructions given including taking the trial products as prescribed. 
 
Treatment compliance: To ensure treatment compliance, the Investigator will at each visit 
assess the Subject’s compliance by evaluating the drug accountability, glycemic control, 
amount of time in auto mode, adherence to the visit schedule, completion of the Subject’s diary, 
and the SMPG values in the CareLink Clinical Report. If a Subject is being non-compliant with 
the treatment, then the Investigator must discuss this with the Subject and emphasize the 
importance of being in compliance. 
 
 
7 
Trial supplies 
 
Trial supplies comprise trial products and auxiliary supplies.  
 
Trial products must not be dispensed to any person not included in the trial. Trial product must 
not be used if it does not appear clear and colorless. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
28 of  40 
 
7.1 Trial products 
 
Table 7–1 
The following will be provided by Novo Nordisk  
 
Trial product 
Strength 
Dosage form 
Route of 
administration
Faster aspart (Fiasp®) 
(IMP) 
100 U/mL 
Solution for 
injection in vial, 
10 mL 
s.c. 
Insulin aspart (NovoLog®) 
(IMP) 
100 U/mL 
Solution for 
injection in vial, 
10 mL 
s.c. 
 
 
7.2 Labelling 
 
 
Labelling of the trial products will be in accordance with local regulations and trial 
requirements. Labelling will include the product related requirements and precautions. 
 
 
 
 
7.3 Storage 
 
Table 7–2 
Storage of trial products 
 
Trial product 
Storage conditions 
(not-in-use) 
In-use conditions 
In-use time* 
Faster aspart (Fiasp®) 
Store in refrigerator (2°C – 8°C) 
Do not freeze 
Protect from light 
Store below 30°C 
Do not refrigerate 
Do not freeze 
Protect from light 
Use within 4 weeks 
 
 
Insulin aspart 
(NovoLog®) 
 
Store in refrigerator (2°C – 8°C) 
Do not freeze 
Protect from light 
Store below 30°C 
Do not refrigerate 
Do not freeze 
Protect from light 
 
 
Use within 4 weeks 
* In-use time starts when vial is removed from refrigerator (dispensing at site). 
 
When the trial product is in the pump reservoir the in-use condition is to keep it below 37°C 
for a maximum of 6 days. Therefore the trial products in the pump reservoir should be 
discarded after no more than 6 days of use or after exposure to temperatures that exceeds 
37°C. 
 
The Investigator must ensure the availability of proper storage conditions, and also record 
and evaluate the temperature.  
 


 
29 of  40 
 
 
7.4 Drug accountability and destruction 
 
Drug accountability is the responsibility of the Investigator. The Investigator or designee 
will perform the drug accountability at each dispensing visit and will destroy the 
investigational product onsite according to site SOPs.   
 
Subjects are instructed to return all used, partly used and unused trial product at each 
dispensing visit, and then finally at end of treatment. 
 
7.5 Auxiliary supplies 
 
The Subject will use their own insulin pump, insulin infusion sets, reservoirs and sensors during 
the trial. 
 
7.5.1 
Auxiliaries supplied by the site 
 
• Bayer Contour® Next Link meters, and strips, lancets and control solution for 
BG meters for subjects who do not have a personal meter 
• Syringes for injection of insulin (for use with vial) 
 
 
8 
Randomization  Procedure  
 
At randomization (Visit 2) the Subject will be randomized to either Fiasp® or 
NovoLog® in a 1:1 manner at the first cross over period to the two different treatment 
arms described below. At the second cross over period (Visit 8) the Subject will be 
given the comparative treatment.  
 
• Fiasp® 
• NovoLog® 
 
 
9 
Adverse events, hypoglycemia, hyperglycemia, infusion site 
reactions,   technical complaints and pregnancies 
 
9.1 
Definitions 
 
9.1.1 
Adverse events 
 
An AE is any untoward medical occurrence in a Subject administered a product, and 
which does not necessarily have a causal relationship with this treatment. 
 
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally associated with the use of a product, 


 
30 of  40 
 
whether or not considered related to the product. AE collection will begin after the 
Subject signs the Informed Consent. 
 
The current version of our local Summary of Product Characteristics (US Product 
Information) or any updates thereof will be used for assessment of expectedness for 
adverse events. 
 
An AE includes: 
• A clinically significant worsening of a concomitant illness 
• A clinical laboratory AE (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ 
toxicity and is of a severity that requires active management. Active management 
includes active treatment or further investigations, for example change of medicine 
dose or more frequent follow-up due to the abnormality 
 
The following should not be reported as AEs: 
• Pre-existing conditions, including those found as a result of screening 
procedures (pre- existing conditions should be reported as medical history or 
concomitant illness) 
• Pre-planned procedures unless the condition for which the procedure was 
planned has worsened from signing the Informed Consent 
• Non-serious hypoglycemia  
• Non-serious unexplained hyperglycemia  
 
 
The following three definitions are used when assessing an AE: 
• Severity 
• Mild - no or transient symptoms, no interference with the Subject's daily 
activities 
• Moderate - marked symptoms, moderate interference with the 
Subject's daily activities 
• Severe - considerable interference with the Subject's daily activities; 
unacceptable 
• Causality 
The following terms are used when assessing the relationship between an AE and 
the relevant trial product(s): 
 
• Probable - good reason and sufficient documentation to 
assume a causal relationship 
• Possible - a causal relationship is conceivable and cannot be dismissed 
• Unlikely - the event is most likely related to etiology other than the trial product 
• Final outcome: 


 
31 of  40 
 
• Recovered/resolved - the Subject has fully recovered, or by medical or 
surgical treatment the condition has returned to the level observed at 
the first trial-related activity after the Subject signed the informed 
consent 
• Recovering /Resolving - the condition is still recovering/resolving at the end of 
the trial 
• Recovered/resolved with sequelae - the Subject has recovered from the 
condition, but with lasting effect due to a disease, injury, treatment or 
procedure. If a sequela meets an SAE criterion, the AE must be reported 
as an SAE 
• Not recovered/not resolved - the condition of the Subject has not 
improved and the symptoms are unchanged, or the outcome is not known 
• Fatal - this term is only applicable if the Subject died from a condition 
related to the reported AE. Outcomes of other reported AEs in a Subject 
before he/she died should be assessed as "recovered/resolved", 
"recovering/resolving", "recovered/resolved with sequelae" or "not 
recovered/not resolved". An AE with fatal outcome must be reported as an 
SAE 
• Unknown - this term is only applicable if the Subject is lost to follow-up 
 
 
       9.1.2 Adverse reaction 
 
 
An Adverse Reaction (AR) is an Adverse Event for which the causal relationship between the 
Product and the Adverse Event is suspected. 
 
                  9.1.3              Serious Adverse Event 
An SAE is an experience that at any dose results in any of the following: 
• Death 
• A life-threatening experience 
• In-patient hospitalization or prolongation of existing hospitalization 
• A persistent or significant disability or incapacity 
• A congenital anomaly or birth defect 
• Important medical events that may not result in death, be life threatening or 
require hospitalization may be considered an SAE when - based on appropriate 
medical judgement they may jeopardize the Subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in the definition of SAE 
• Suspicion of transmission of infectious agents must always be considered an 
SAE 
 
 
 


 
32 of  40 
 
9.1.4  Serious Adverse Reaction 
   
  An Adverse event that will fulfill both the criteria for a Serious Adverse event and the criteria 
for an Adverse Reaction.            
 
             9.1.5 
Non-serious adverse events 
 
 
A non-serious AE is any AE which does not fulfill the definition of an SAE. 
 
 
             9.1.6        Hypoglycemic episodes 
 
 
All plasma glucose values: 
• ≤ 70 mg/dL 
• > 70 mg/dL occurring in conjunction with hypoglycemic symptoms 
 
 
Upon onset of a hypoglycemic episode the Subject is recommended to measure plasma 
glucose every 15 minutes until the SMPG value is > 70 mg/dL or symptoms have been 
resolved in accordance to current guidelines. 
 
If the Subject experiences a severe hypoglycemic episode (i.e. if the subject was not 
able to treat themselves) the Subject should be instructed to contact the site staff as 
soon as possible after recovery for further guidance on titration. 
 
 
            9.1.7          Unexplained hyperglycemic episodes 
 
Any unexplained hyperglycemic episode with SMPG values ≥ 300 mg/dL and no apparent 
explanation (i.e. no apparent medical, dietary, insulin dosage, or pump failure reason) must 
be recorded in the Subjects’ diary. Symptoms should be treated in accordance with 
instructions from Investigator.  
 
All hyperglycemic episodes that are not unexplained should be reported as AEs in 
accordance to section 09 if the Investigator judges that the hyperglycemic episode is 
clinically significant. 
 
            9.1.8        Infusion site reactions 
 
If suspicion of an infusion site reaction occurs, the Subject should be instructed to call the 
site staff as soon as possible for further guidance. 
 
Infusion site reactions at the site of trial product(s) administration must be recorded as an AE 
throughout the trial from start of screening (Visit 1) until the end of treatment visit (Visit 14). 


 
33 of  40 
 
 
  9.2 
Reporting of adverse events 
 
The Investigator is responsible for reporting all adverse events, including SAE’s to the 
competent authority and IRB based on federal regulations and IRB policies. All events 
meeting the definition of an AE must be collected and reported. This includes events from 
randomization until the last phone contact/site visit..  
 
During each contact with the trial site staff, the Subject should be asked about AEs. 
 
All AEs should be recorded by the Investigator on an AE Form. The Investigator 
should report the diagnosis, if available. If no diagnosis is available, the Investigator 
should record each sign and symptom as individual AEs using separate AE Forms. 
 
 
9.2.1 
Timelines for initial reporting of serious adverse events 
 
The Investigator should complete the following within the specified timelines: 
• SAEs - The AE Form and notification to the Novo Nordisk within 24 hours and to the 
IRB, according to the IRB guidelines. As a minimum, the following should be reported to 
NovoNordisk: Study name, Patient identification (e.g. subject number, initials, sex, age), 
Event (Preferably diagnosis), Trial drug, Reporter, Causality, Outcome. 
 
 
9.2.2 
              Follow-up of adverse events 
 
 
Follow-up information must be followed up according to the following: 
•  SAEs - All SAEs should be followed until the outcome of the event is 
"recovered/resolved", "recovered/resolved with sequelae" or "fatal", and until all 
queries have been resolved. Cases of chronic conditions, cancer or AEs ongoing 
at time of death (where death is due to another AE) may be closed with the 
outcome "recovering/resolving" or "not recovered/not resolved". Cases can be 
closed with the outcome of "recovering/resolving" when the Subject has 
completed the follow-up period and is expected by the Investigator to recover. 
The SAE follow-up information should only include new (e.g. corrections or 
additional) information and must be reported within 24 hours of the 
Investigator's first knowledge of the information. This is also the case for 
previously non-serious AEs which subsequently become SAEs 
• Non-serious AEs - Non-serious AEs should be followed until the outcome of the event 
is"recovered/resolved" or "recovered/resolved with sequelae" or until the end of the follow-
up period stated in the protocol, whichever comes first. Cases of chronic conditions, cancer 
or AEs ongoing at time of death (where death is due to another AE) may be closed with the 
outcome "recovering/resolving " or "not recovered/not resolved". 
 


 
34 of  40 
 
9.3 
Pregnancies 
 
9.3.1 
Pregnancies in female Subjects 
 
Female Subjects must be instructed to notify the Investigator immediately if they become 
pregnant during the trial until end of treatment. The Investigator must report any 
pregnancy in Subjects who have received trial product(s). 
 
The Investigator should follow the pregnancy until the pregnancy outcome and the new-
born infant is one month of age. 
 
The Investigator should report information about the pregnancy, pregnancy outcome, and 
health of the new-born infant(s), as well as AEs in connection with the pregnancy and 
AEs in the fetus and new-born infant. 
 
Investigator to report all pregnancies in trial subjects occurring during use of a Novo 
Nordisk Product to Novo Nordisk. 
 
 
10 Quality Control Procedures 
 
During the course of the trial, site staff will perform frequent quality checks through the 
duration of the study to ensure that the protocol is adhered to, that all issues have been 
recorded, and to monitor drug accountability. Data reviewed includes, but is not limited 
to, subject source charts, laboratory results, Medtronic Carelink reports, drug logs, and  
Subject diaries.  
 
 
 
11 Data Handling and Record Keeping 
 
Record keeping for this study will be handled by the Investigative site in accordance to the 
regulatory requirements.  
 
Subject's data will be handled as follows: 
  Data already collected will be retained by the Investigator entered into the database and used for   
  the trial report. 
Safety events will be reported to Novo Nordisk and regulatory authorities according to 
regulatory requirements. 
Data will be kept onsite at the Investigators location in a secure area through the duration of the 
trial and then moved offsite into a secure storage location for the required time post trial 
completion. 
 
 


 
35 of  40 
 
  12 Statistical considerations 
 
12.1 General considerations 
All efficacy and safety endpoints will be summarized and analyzed using the full analysis set.  
 
 Estimated mean treatment differences (or ratios) will be presented together with two-sided 95% 
confidence interval (CI) for all endpoints analyzed. Data collected before randomization will 
only be summarized descriptively. 
 
Recognizing that there may be more adjustment by the 670G software in the first two weeks of 
treatment in each crossover period, analyzation of data will be focused on week 3-7 of each 
cross over period.  
  
12.2 Sample size calculation 
The primary objective of the trial is to compare glycemic control with Fiasp® versus 
NovoLog® when used in the MiniMed 670G System in Auto Mode. The primary objective will 
be addressed by estimating the treatment difference (including 95% confidence intervals (CI)) 
for HbA1c and the PPG increment at 1 hour (meal test) after 6 weeks of treatment. 
 
The trial population is assumed to be similar to that of  a prior study with Fiasp® (reference 8) 
(exploratory, double-blind, randomized, 3×14-days, cross-over, single-center, active controlled 
trial evaluating external continuous subcutaneous infusion of insulin aspart in three different 
formulations in adult subjects with type 1 diabetes). In that trial, the within-subject standard 
deviation (SD) for 1-hour PPG increment (meal test) across all periods was 5.81, while the 
estimated treatment difference between Fiasp® and NovoLog® was -1.81 mmol/L (95% CI: -
2.96 to -0.67).  
 
 
Assuming that the treatment difference will be no less than that seen in that study, there is at 
least 80% power to detect a treatment difference with 36 subjects. Accounting for 10% 
dropouts, a total of 40 subjects should be randomized. 
 
The subject population is furthermore in keeping with the treatment difference seen in the Onset 
5 study (Reference 10), which was (ETD -0.91 mmol/L [95% CI -1.43; -0.39]; P = 0.001) 
 
12.3   Primary endpoints 
The primary endpoint is PPG increment at 1 hour (meal test) after 6 weeks of treatment (i.e. the 
difference in 1-hour PPG and PPG immediately prior to bolus administration). The primary 
endpoint will be used to address the primary objective of investigating postprandial glycemic 
control with Fiasp® compared to NovoLog® when used with the MiniMed 670G System in 
 ‘Auto Mode’.  
 
The primary endpoint will be analyzed for subjects who perform the meal tests in both 
treatment periods, using the MiniMed 670G System in ‘Auto Mode’. In other words, the 
treatment difference will be estimated in subjects who are able to manage 14 days of treatment 
with both Fiasp® and NovoLog® using the MiniMed 670G System in ‘Auto Mode’. 
 


 
36 of  40 
 
The mean treatment difference stipulated by the estimand (including 95% CI), alongside 
treatment means, will be derived from a linear mixed model for repeated measurements. The 
model will include treatment, and period as factors, and subject as a random effect. Because the 
treatment difference is estimated in the population of subjects who are able to manage treatment 
with both Fiasp® and NovoLog®, i.e. subjects who contribute meal test data under both 
treatments, no special methods are needed to address missing data for the primary estimand. 
 
 
12.4 Secondary endpoints 
 
- 
Difference in HbA1c between periods will be assessed.  
- 
Glycemic excursion parameters. Time spent within glycemic ranges as below will be 
reported and analyzed. Time spent in specific ranges will be expressed as a percentage of 
total time on treatment.  
o Time spent (%) within 70-180 mg/dl 
o Time spent (%) < 70 mg/dl  
o Time spent (%) >200 mg/dl 
o Hypoglycemia  
o Severe hypoglycemia 
 
The time spent within 70-180 mg/dL, <70 mg/dL, and >200 mg/dL, and hypoglycemia is 
defined for each subject as the accumulated time in hours spent within the above intervals as 
recorded by the continuous glucose monitoring component of the MiniMed 670G system. 
Comparison between the NovoLog®  and Fiasp®  groups will be analyzed by using linear 
mixed modeling for repeated measurements for each range. The models will include treatment 
and period as factors, and subject as a random effect.  
 
- 
Insulin related parameters 
o Total daily dose 
o change in %bolus and %basal from baseline 
o Auto basal / basal amount (per day) 
o Change in insulin : carbohydrate ratio from baseline  
o Active insulin time 
 
 
- 
Pump related parameters 
o Time spent (%) in auto mode 
o Time spent (%) in manual mode 
o Auto mode exits (with reasons for exit)  
o Infusion site reactions reported by patient 
o Occlusion events reported by patient 
 
Secondary endpoints will be assessed through duration of follow-up in the study.  
 
 
 
 


 
37 of  40 
 
13 Ethics 
 
The trial will be conducted in compliance with ICH GCP and applicable regulatory 
requirements, and in accordance with the Declaration of Helsinki. 
 
All Subjects included in the trial will be randomized to either Fiasp® or NovoLog®. 
 
The most common side effect of all available insulin preparations is hypoglycemia. The 
Investigator will explain to the Subject how they should check their BG meter and what 
precautions to take. 
 
Subjects randomized in the trial will be transferred to a treatment regimen anticipated to 
be either better than or equal to the treatment they receive at the time they entered the 
trial.  
 
At the end of treatment, the Subject and Investigator will decide on the best available 
treatment on the market.  
 
 
13.1 
Informed Consent 
 
In seeking and documenting Informed Consent, the Investigator must comply with 
applicable regulatory requirement(s) and adhere to ICH GCP and the requirements 
in the Declaration of Helsinki. 
 
Before any trial-related activity, the Investigator must give the Subject verbal and 
written information about the trial and the procedures involved in a form that the 
Subject can read and understand. 
 
The Subjects must be fully informed of their rights and responsibilities while 
participating in the trial as well as possible disadvantages of being treated with the trial 
products. 
 
The Investigator must ensure the Subject has ample time to come to a decision whether 
or not to participate in the trial. A voluntary, signed, and personally dated Informed 
Consent must be obtained from the Subject before any trial-related activity. 
 
The responsibility for seeking Informed Consent must remain with the Investigator, 
but the task may be delegated by the Investigator to a medically qualified person, in 
accordance with local requirements. The Informed Consent must be signed and 
personally dated by the person who seeks the Informed Consent before any trial-
related activity. 
 
If information becomes available that may be relevant to the Subject's willingness to 
continue participating in the trial, the Investigator must inform the Subject in a timely 


 
38 of  40 
 
manner, and revised Informed Consent must be provided and a new Informed Consent 
must be obtained. 
 
14 Protocol compliance 
 
Deviations from the protocol should be avoided. 
 
Deviations should be documented and explained in at minimum in the Subject’s source 
chart. 
 
15 Audits and inspections 
 
The Investigator and the site staff have an obligation to cooperate and assist in audits and 
inspections from domestic or foreign regulatory authorities or from IRBs/IECs.  This 
includes giving auditors and inspectors direct access to all source documents and other 
documents at the trial site relevant to the clinical trial.  
 
 
 
16 Investigator Responsibilities 
 
 
All staff will conduct the trial in compliance with ICH GCP, applicable regulatory 
requirements and the Declaration of Helsinki. 
 
 
The Investigator is accountable for the conduct of the trial. If any tasks are delegated, the 
Investigator shall maintain a list of appropriately qualified persons to whom he/she has 
delegated specified significant trial-related duties. The Investigator shall ensure that there 
is adequate training for all staff participating in the conduct of the trial. It is the 
Investigator's responsibility to supervise the conduct of the trial and to protect the rights, 
safety, and well-being of the Subjects. 
 
A qualified physician, who is an Investigator or a sub-Investigator for the trial, shall be 
responsible for all trial-related medical decisions. 
 
The Investigator must ensure adequate supervision of the conduct of the trial at the trial site.  
 
17 Institutional Review Boards and regulatory authorities 
 
 
Institutional Review Boards 
 
Written approval shall be obtained from an IRB prior to commencement of the trial. 
 


 
39 of  40 
 
During the trial, the Investigator should  promptly report the following to the IRB in 
accordance with local requirements: updates to IB, unexpected SAEs as applicable to IRB 
guidelines, protocol amendments, deviations to the protocol according to the IRB 
guidelines, new information that may affect adversely the safety of the Subjects or the 
conduct of the trial (including new benefit-risk analysis in case it will have an impact on 
the planned follow-up of the Subjects), annually written summaries of the trial status, and 
other documents as required by the local IRB. 
 
The Investigator should maintain an accurate and complete record of all submissions 
made to the IRB/IEC. The records must be filed in the Investigator trial master file and 
copies must be sent to Novo Nordisk. 
 
Regulatory Authorities 
 
Regulatory authorities will receive the clinical trial application, protocol amendments, and 
reports on SAEs, according to national requirements. 
 
18 Publication Plan 
 
  Public disclosure of results will be published within 4 months of completion and will include a       
  publication of a paper in at least one scientific journal and one presentation (poster or oral  
  presentation) at a scientific meeting. 
 
 
19 References 
 
 
1. Thabit H, Tauschmann M, Allen JM, et al; APCam Consortium and AP@home Consortium. Home 
Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med 2015; 373: 2129-40. 
 
2.Bergenstal RM, et al. JAMA. 2016;316(13):1407-1408. 
3. Garg SK, et al. Diabetes Technol Ther. 2017;19(3):155-163. 
4.  Minimed 670G System User Guide (2016) 
5. Heise T, Zijlstra E, Nosek L, et al. Pharmacological properties of faster-acting insulin aspart vs insulin 
aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, 
double-blind, 
crossover trial. Diabetes Obes Metab 2017; 19:208-215. 
6. Heise T, Pieber TR, Danne T, et al. A Pooled Analysis of Clinical Pharmacology Trials Investigating 
the Pharmacokinetic and  Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in 
Adults with Type 1 Diabetes. Clin Pharmacokinet 2017 


 
40 of  40 
 
 
7. Russell-Jones D, Bode B, de Block C, et al. Fast-Acting Insulin Aspart Improves Glycemic 
Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, 
Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1). Diabetes Care 
2017;40:943–950I 
 
8. Bode BW, Johnson JA, Hyveled L et al. Improved Postprandial Glycemic Control with Faster-
Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin 
Infusion. Diabetes Technol Ther 2017; 19(1):25-33. 
 
9.  Zijlstra, et al.  Journal of Diabetes Science and Technology 2018, Vol. 12(1) 145–151 
 
10.  Klonoff DC,  Evans ML,  Lane W, et al. A randomized, multicentre trial evaluating the 
efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in 
adults with type 1 diabetes (onset 5)  Diabetes Obes Metab. 2018 Dec 9. doi: 
10.1111/dom.13610. [Epub ahead of print] 
 
11. Agiostratidou G, Anhalt H, Ball D Standardizing Clinically Meaningful Outcome Measures 
Beyond HbA1c for Type 1Diabetes: A Consensus Report of the American Association of 
ClinicalEndocrinologists, the American Association of Diabetes Educators, the American 
Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and 
Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D  
Exchange. Diabetes Care. 2017 Dec;40(12):1622-1630.